EGFr Expression and Survival in Lung Cancer
Author Information
Author(s): D. Vealel, N. Kerr, G.J. Gibson, P.J. Kelly, A.L. Harris
Primary Institution: Freeman Hospital, University of Newcastle upon Tyne, Imperial Cancer Research Fund Clinical Oncology Unit
Hypothesis
Does the expression of epidermal growth factor receptor (EGFr) in non-small cell lung cancer (NSCLC) correlate with long-term survival?
Conclusion
Higher levels of EGFr are associated with shorter survival in patients with non-small cell lung cancer.
Supporting Evidence
- Patients with high EGFr levels had a median survival of less than 5 years.
- All patients with EGFr levels greater than 35 fmol mg-1 died within 5 years.
- Seven patients with lower EGFr levels survived beyond 5 years.
Takeaway
This study found that patients with more EGFr in their lung tumors tend to live for a shorter time after surgery.
Methodology
The study analyzed EGFr expression in tumor samples from 19 patients who underwent surgery for NSCLC and correlated it with their survival outcomes.
Limitations
The study had a small sample size and results need confirmation in larger studies.
Participant Demographics
Patients included 10 squamous, 7 adenocarcinomas, and 2 large cell carcinomas, with a median age of 60 years.
Statistical Information
P-Value
0.01
Statistical Significance
p=0.01
Want to read the original?
Access the complete publication on the publisher's website